angiotensin-i has been researched along with Cushing-Syndrome* in 3 studies
2 review(s) available for angiotensin-i and Cushing-Syndrome
Article | Year |
---|---|
[Angiotensin I, angiotensin II, angiotensin III].
Topics: Angiotensin I; Angiotensin II; Angiotensin III; Biomarkers; Chromatography, High Pressure Liquid; Cushing Syndrome; Diagnosis, Differential; Diagnostic Techniques, Endocrine; Humans; Hyperaldosteronism; Hypertension; Hypertension, Renovascular; Myocardial Infarction; Radioimmunoassay; Reference Values; Renin-Angiotensin System; Specimen Handling; Water-Electrolyte Imbalance | 2005 |
[The renin-angiotensin system. Physiopathological aspects and clinical implications of hypertensive syndromes. A survey].
In this review the physiologic role of the renin-angiotensin system in blood pressure regulation is discussed, and the alterations of the renin secretion in various forms of hypertension are examined. Furthermore a critical appraisal is made of the diagnostic and prognostic value of the plasma renin activity assay in hypertensive diseases. Topics: Acromegaly; Aldosterone; Angiotensin I; Angiotensin II; Captopril; Cushing Syndrome; Glycoproteins; Humans; Hyperaldosteronism; Hypertension; Kidney; Kidney Diseases; Prostaglandins; Receptors, Adrenergic; Receptors, Angiotensin; Renin; Sodium; Sympathetic Nervous System; Teprotide | 1981 |
1 other study(ies) available for angiotensin-i and Cushing-Syndrome
Article | Year |
---|---|
Effects of corticotropin-releasing factor and other materials on adrenocorticotropin secretion from pituitary glands of patients with Cushing's disease in vitro.
ACTH responsiveness in vitro to synthetic corticotropin-releasing factor (CRF), lysine-8-vasopressin, and cAMP was examined using superfusion of pituitary adenoma tissue and the nonadenomatous tissue from 16 patients with Cushing's disease. Sensitivity of adenomas to lysine-8-vasopressin and cAMP was similar to that of nonadenomatous tissues; however, sensitivity of adenomas to CRF was lower than that of nonadenomatous tissues in 7 of 16 patients. CRF-induced ACTH secretion from adenomas was inhibited by Ca2+-free medium in all instances and by dexamethasone and somatostatin in some. Angiotensins I and II stimulated ACTH secretion from both adenomas and nonadenomatous tissues, while angiotensin I-induced ACTH secretion was inhibited by angiotensin-converting enzyme inhibitor. These results suggest that the sensitivity of the pituitary corticotroph adenomas to CRF in some patients is low. This may be due to an abnormality of the step(s) before cAMP formation, such as the CRF receptor. Topics: Adenoma; Adrenocorticotropic Hormone; Angiotensin I; Bromocriptine; Calcium; Corticotropin-Releasing Hormone; Cushing Syndrome; Cyclic AMP; Dexamethasone; Gonadotropin-Releasing Hormone; Humans; In Vitro Techniques; Lypressin; Pituitary Gland; Pituitary Neoplasms; Radioimmunoassay; Somatostatin; Thyrotropin-Releasing Hormone | 1984 |